Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?

Journal: Geburtshilfe Und Frauenheilkunde
Published:
Abstract

[This corrects the article DOI: 10.1055/a-2562-8469.].

Relevant Conditions

Breast Cancer

Similar Publications

We couldn’t find any related articles. Please check for more on the main search page.